You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(02096.HK)與塔吉瑞就非小細胞肺癌藥物TGRX-326訂立合作協議
格隆匯 09-02 18:17

格隆匯9月2日丨先聲藥業(02096.HK)發佈公吿,海南先聲再明醫藥股份有限公司(公司附屬公司)的全資附屬公司(先聲再明)與深圳市塔吉瑞生物醫藥有限公司(塔吉瑞)就TGRX-326訂立合作協議。根據該協議,先聲再明將獲得TGRX-326在中國內地的獨家商業化權益,塔吉瑞將獲得逾2,000萬美元首付款,並將向先聲再明支付推廣服務費。本次合作將進一步強化集團在肺癌領域的產品佈局。

TGRX-326是一種間變性淋巴瘤激酶(ALK)和c-ROS原癌基因(ROS1)雙重受體酪氨酸激酶(RTK)抑制劑,是最新一代治療ALK/ROS1融合基因陽性驅動的非小細胞肺癌(NSCLC)原創1類新藥。TGRX-326在臨牀前研究及臨牀I期試驗中表現出良好的抗腫瘤療效和安全性,可用於治療ALK/ROS1基因變異的NSCLC患者。此外TGRX-326具有很高的血腦屏障通透性,對發生腦轉移的NSCLC可發揮很好的作用。

塔吉瑞是一家處於臨牀階段的高科技醫藥研發公司,致力於研發針對癌症患者(尤其是對現有治療方法耐藥╱難治的癌症患者)的新一代靶向療法。塔吉瑞自主搭建了前沿高效的小分子藥物開發系列平台,具備藥物設計、篩選、評價、優化等創新研發能力。成立至今,塔吉瑞已累計獲得包括中國、美國、歐洲、日本等區域在內的170餘項專利授權。多個潛在的同類最佳化合物正處於跨國臨牀試驗的不同階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account